Author

S. Buonamici

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

J. Taylor· 2 shared M. Seiler· 2 shared O. Abdel-Wahab· 2 shared A. A. Lane· 1 shared A. Louissaint· 1 shared A. Tracz· 1 shared B. J. E. Martin· 1 shared D. G. Tang· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Taylor

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS/AML

E. C. Wheeler, B. J. E. Martin, W. C. Doyle, R. A. Gorelov, M. Donahue, J. C. Jann, O. Abdel-Wahab, J. Taylor, M. Seiler, S. Buonamici, R. Belizaire, K. Adelman, Z. Tothova

The paper shows SF3B1 splicing modulators impair DNA damage response in cohesin-mutant MDS/AML, leading to increased sensitivity to PARP inhibitors and chemotherapy.

bioRxiv · Sep 26, 2022Cancer Biology

Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis

K. Togami, S. S. Chung, V. Madan, L. Cabal-Hierro, J. Taylor, S. S. Kim, G. K. Griffin, M. Ghandi, J. Li, Y. Y. Li, F. Angelot-Delettre, S. Biichle, M. Seiler, S. Buonamici, S. B. Lovitch, , A. A. Lane

The paper identifies sex-biased ZRSR2 mutations in BPDCN that impair pDC activation and apoptosis, linking X chromosome mutations to male-predominant leukemia.

bioRxiv · Oct 29, 2020Cancer Biology

Dysregulated Alternative Splicing Landscape Identifies Intron Retention as a Hallmark and Spliceosome as a Therapeutic Vulnerability in Aggressive Prostate Cancer

D. Zhang, Q. Hu, Y. Ji, H.-P. Chao, A. Tracz, J. Kirk, S. Buonamici, P. Zhu, J. Wang, S. Liu, D. G. Tang

The paper identifies intron retention as a hallmark of aggressive prostate cancer and highlights the spliceosome as a therapeutic target by analyzing splicing dysregulation across prostate cancer progression.

bioRxiv · May 11, 2019 · PreprintCancer Biology